We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$122M
Cap. Flow
-$172M
Cap. Flow %
-6.22%
Top 10 Hldgs %
38.62%
Holding
217
New
37
Increased
33
Reduced
47
Closed
5

Top Buys

Rank Stock Value
1
ZTS icon
Zoetis
ZTS
+$17M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.8M
3
NVO
Novo Nordisk
NVO
+$8.1M
4
ELV icon
Elevance Health
ELV
+$7.92M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.37M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$42.7M
2
PFE icon
Pfizer
PFE
+$40.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$30.9M
4
UNH icon
UnitedHealth
UNH
+$21M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Real Estate 2.75%
3 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MASI
101
DELISTED
Masimo
MASI
$4.24M 0.15%
34,020
-14,000
-29% -$1.55M
DGX icon
102
Quest Diagnostics
DGX
$25.9B
$4.21M 0.15%
+39,000
New +$4.28M
LOXO
103
DELISTED
Loxo Oncology, Inc
LOXO
$4.2M 0.15%
24,595
+14,230
+137% +$2.39M
FOMX
104
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.17M 0.15%
727,205
-203,193
-22% -$1.16M
ALBO
105
DELISTED
Albireo Pharma Inc
ALBO
$4.12M 0.15%
125,000
– –
STE icon
106
Steris
STE
$22.5B
$4.03M 0.15%
35,203
+12,800
+57% +$1.45M
A icon
107
Agilent Technologies
A
$39.2B
$4.01M 0.15%
+56,800
New +$3.76M
NVRO
108
DELISTED
NEVRO CORP.
NVRO
$3.92M 0.14%
68,760
+15,770
+30% +$986K
PBYI icon
109
Puma Biotechnology
PBYI
$402M
$3.82M 0.14%
83,340
– –
STRO icon
110
Sutro Biopharma
STRO
$411M
$3.75M 0.14%
+25,000
New +$3.77M
TSRO
111
DELISTED
TESARO, Inc.
TSRO
$3.71M 0.13%
94,970
– –
PRAH
112
DELISTED
PRA Health Sciences, Inc.
PRAH
$3.58M 0.13%
32,460
– –
AVDL
113
DELISTED
Avadel Pharmaceuticals
AVDL
$3.58M 0.13%
814,588
– –
VRNA
114
DELISTED
Verona Pharma
VRNA
$3.44M 0.12%
275,000
– –
MRNS
115
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.36M 0.12%
+84,057
New +$2.39M
ZGNX
116
DELISTED
Zogenix, Inc.
ZGNX
$3.28M 0.12%
66,182
+30,830
+87% +$1.57M
HZNP
117
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.19M 0.12%
162,900
– –
SNR
118
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$3.12M 0.11%
528,919
– –
PTLA
119
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.07M 0.11%
115,448
+25,470
+28% +$832K
NITE
120
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$3.06M 0.11%
+150,000
New +$3.08M
CRL icon
121
Charles River Laboratories
CRL
$11.3B
$3.05M 0.11%
22,670
– –
OVID icon
122
Ovid Therapeutics
OVID
$442M
$3.04M 0.11%
535,824
– –
VAR
123
DELISTED
Varian Medical Systems, Inc.
VAR
$2.94M 0.11%
26,227
– –
WELL icon
124
Welltower
WELL
$170B
$2.93M 0.11%
45,560
– –
SGMO
125
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.91M 0.11%
171,889
+51,377
+43% +$781K
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Tekla Capital Management held 217 positions worth $2.76B, up 4.6% from $2.64B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management withdrew a net $172M in Q3 2018, closing 5 positions and reducing 47 holdings. Its most notable exit was Welltower Inc., an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Quest Diagnostics worth $4.21M.

  • Tekla Capital Management's largest Q3 2018 buy was Quest Diagnostics: 39,000 shares worth $4.21M.
  • Tekla Capital Management added most to Zoetis in Q3 2018, an estimated $17M increase.
  • Tekla Capital Management's biggest Q3 2018 reduction was Merck, cutting an estimated $42.7M.
  • Tekla Capital Management fully exited Welltower Inc. in Q3 2018, selling an estimated $11.9M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.76B portfolio in Q3 2018.
  • Tekla Capital Management opened 37 new positions and closed 5 in Q3 2018.
  • Tekla Capital Management's portfolio value rose 4.6% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.